ABOS|EPS -$2.00 vs -$0.46 est (-334.8%)|Net Loss $121.3MAcumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for Alzheimer’s disease. Their lead clinical candidate, sabirnetug, selectively targets toxic soluble amyloid beta oligomers.
For the year ended December 31, 2025, Acumen reported a net loss per common share (EPS) of $(2.00). Based on the provided financial statements, the company did not report any revenue for 2025. The company’s total net loss for the year was $121.3 million.
Acumen concluded 2025 with $116.9 million in cash, cash equivalents, and marketable securities. Operating losses were primarily driven by research and development expenses, which totaled $104.9 million. Furthermore, in March 2026, the company announced a $35.75 million private placement to advance its preclinical candidates.
A detailed analysis of Acumen Pharmaceuticals, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.